Diaz-delCastillo Marta, Woldbye David P D, Heegaard Anne Marie
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, Copenhagen Ø 2100, Denmark.
Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N 2300, Denmark.
Neuroscience. 2018 Sep 1;387:162-169. doi: 10.1016/j.neuroscience.2017.08.050. Epub 2017 Sep 7.
Chronic pain is a serious condition that significantly impairs the quality of life, affecting an estimate of 1.5 billion people worldwide. Despite the physiological, emotional and financial burden of chronic pain, there is still a lack of efficient treatments. Neuropeptide Y (NPY) is a highly conserved endogenous peptide in the central and peripheral nervous systems of all mammals, which has been implicated in both pro- and antinociceptive effects. NPY is expressed in the superficial laminae of the dorsal horn of the spinal cord, where it appears to mediate its antinociceptive actions via the Y1 and Y2 receptors. Intrathecal administration of NPY in animal models of neuropathic, inflammatory or postoperative pain has been shown to cause analgesia, even though its exact mechanisms are still unclear. It remains to be seen whether these promising central antinociceptive effects of NPY can be transferred into a future treatment for chronic pain.
慢性疼痛是一种严重的病症，会显著损害生活质量，据估计全球有15亿人受其影响。尽管慢性疼痛会带来生理、情感和经济负担，但仍然缺乏有效的治疗方法。神经肽Y（NPY）是所有哺乳动物中枢和外周神经系统中高度保守的内源性肽，它与痛觉促进和痛觉抑制作用均有关联。NPY在脊髓背角的浅层表达，似乎通过Y1和Y2受体介导其痛觉抑制作用。在神经性、炎症性或术后疼痛的动物模型中，鞘内注射NPY已显示出能产生镇痛效果，尽管其确切机制仍不清楚。NPY这些有前景的中枢痛觉抑制作用能否转化为未来慢性疼痛的治疗方法还有待观察。
